Senna Use in Chronic Kidney Disease (CKD)

Efficacy and Safety of Senna in CKD

Senna (sennosides) is a stimulant laxative that is metabolized by gut microbiota to active metabolites (rheinanthrone and rhein), which stimulate prostaglandin E2 production and chloride ion secretion, enhancing colonic peristalsis 2, 3
Over 90% of sennosides and their metabolites are excreted in the feces, making it generally safe for use in CKD patients 3

Start with a lower dose (8.6-17.2 mg daily) and titrate based on symptom response and side effects 4
The dose evaluated in clinical trials (1g daily) is higher than commonly used in practice, and 83% of participants in studies reduced their daily dose due to side effects 2, 3
Most commercially available senna products contain 8-9 mg per tablet 3
The American Gastroenterological Association-American College of Gastroenterology conditionally recommends senna for chronic constipation treatment (conditional recommendation, low certainty evidence) 1, 5

Low cost and over-the-counter availability make it accessible for CKD patients 4, 3
Unlike magnesium oxide, which should be avoided in renal insufficiency due to risk of hypermagnesemia, senna does not pose this risk 1, 6

Common side effects include abdominal pain, cramping, and diarrhea, particularly at higher doses 1, 2
Long-term safety data is limited, so periodic reassessment of continued need is recommended 2, 3

Polyethylene glycol (PEG) is recommended as a first-line option for chronic constipation with strong recommendation and moderate certainty evidence 5
Avoid magnesium oxide in CKD patients due to risk of hypermagnesemia 1, 6
Bisacodyl or sodium picosulfate can be used for short-term or rescue therapy 5